What is Annoroad?
Founded in 2012 and headquartered in Beijing, Annoroad Gene Technology is a prominent enterprise within China's genomics industry. It stands as a leading NIPT service provider in China and a premier medical genomics center across Asia. The company specializes in applying next-generation genomics to human health and life science research. Annoroad has garnered numerous accolades, including recognition as a national high-tech enterprise and approval for high-throughput sequencing clinical applications by the NHFPC. It also operates as a gene detection technology demonstration center approved by the NDRC and hosts a Beijing Engineering Laboratory for Precision Medicine and Genetic Engineering. The company has developed proprietary genome sequencing and bioinformatics technologies, supported by advanced high-throughput sequencing and high-performance computing platforms. Annoroad has introduced the NextSeq 550AR sequencer and SolarGenomics, a cloud-based genomic big data platform, establishing a comprehensive product system that spans sequencing instruments, reagents, medical testing, research services, and genomic big data solutions.
How much funding has Annoroad raised?
Annoroad has raised a total of $100M across 1 funding round:
Series C
$100M
Series C (2017): $100M with participation from SBCVC, Shenzhen GTJA Investment Group, Ping An Ventures, and SAIF Partners
Key Investors in Annoroad
SBCVC
SBCVC is a leading venture capital and private equity firm established in China in 2000, managing both USD and RMB funds. They focus on high-tech, high-growth companies across TMT, clean technology, healthcare, consumer/retail, and advanced manufacturing sectors, investing across all company stages and providing strategic and commercial support.
Shenzhen GTJA Investment Group
Shenzhen GTJA Investment Group, founded in 2001 and based in Shenzhen, China, specializes in investments within the healthcare industry, with a particular focus on pharmaceuticals, medical apparatus, and medical services.
Ping An Ventures
Ping An Ventures is part of Ping An Insurance Group, a financial services group headquartered in Shenzhen, China, that specializes in insurance, banking, and investment banking, and invests in various sectors.
What's next for Annoroad?
With substantial enterprise-level backing, Annoroad is strategically positioned to accelerate its research and development initiatives and expand its market reach. The recent major strategic investment will likely fuel advancements in its genomic sequencing technologies and bioinformatics platforms. Future endeavors may include further integration of its cloud-based big data solutions and broadening its comprehensive product system across the entire industry chain. Continued focus on innovation in precision medicine and genetic engineering, supported by its post-doctoral research station, is anticipated to solidify Annoroad's leadership in the Asian genomics landscape.
See full Annoroad company page
